论文部分内容阅读
艾乐替尼是治疗间变性淋巴瘤激酶(ALK)阳性的非小细胞肺癌药物,于2015年12月11日经美国食品和药物管理局批准上市。与前一代ALK抑制剂克唑替尼相比,艾乐替尼在疗效及适应证上均表现出较大优势。本文综述了艾乐替尼的药理作用、药动学、临床研究及不良反应等,供临床参考。
Allitinib was approved as an NSCLC positive for anaplastic lymphoma kinase (ALK) and was approved by the U.S. Food and Drug Administration on December 11, 2015. Compared with the previous generation of ALK inhibitor crizotinib, the efficacy and indications of all showed a great advantage. This article reviews the pharmacological effects of aleatinib, pharmacokinetics, clinical studies and adverse reactions for clinical reference.